Recombinant Human LILRB2/CD85d/ILT4 His-tag Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

The immunoglobulin-like transcript (ILT) molecules comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1, 2). ILT4, also known as CD85d, LIR-2, and LILRB2, is closely related to mouse PIR-B and is primarily expressed on monocytes, dendritic cells (DC), and neutrophils (3, 4). Mature human ILT4 consists of a 440 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain with 3 inhibitory immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64% aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5-9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces tyrosine phosphorylation within its cytoplasmic ITIMs, association with SHP-1, and inhibition of stimulatory signaling (3, 6). ILT4 activation promotes the development of tolerogenic dendritic cells and the subsequent induction of regulatory T cells and CD4⁺ T cell anergy (10-12). Ligation of ILT4 on neutrophils further attenuates immune responses by inhibiting neutrophil phagocytic activity and production of reactive oxygen species (4). ILT4 also binds to multimeric Angiopoietin-like 2, and its ligation supports the expansion of hematopoietic stem cells from cord blood (13). In the brain, ILT4 and mouse PIR-B function as receptors for oligomeric Abeta (1-42) peptide (14).

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: In Vivo.

Showing Publication 1 - 1 of 1.

Publication using 8429-T4	Applications	Species
Tian, J;Ashique, AM;Weeks, S;Lan, T;Yang, H;Chen, HH;Song, C;Koyano, K;Mondal, K;Tsai, D;Cheung, I;Moshrefi, M;Kekatpure, A;Fan, B;Li, B;Qurashi, S;Rocha, L;Aguayo, J;Rodgers, C;Meza, M;Heeke, D;Medfisch, SM;Chu, C;Starck, S;Basak, NP;Sankaran, S;Malhotra, M;Crawley, S;Tran, TT;Duey, DY;Ho, C;Mikaelian, I;Liu, W;Rivera, LB;Huang, J;Paavola, KJ;O'Hollaren, K;Blum, LK;Lin, VY;Chen, P;Iyer, A;He, S;Roda, JM;Wang, Y;Sissons, J;Kutach, AK;Kaplan, DD;Stone, GW; ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms Cancer immunology research 2024-02-23 [PMID: 38393969] (In Vivo, Mouse)	In Vivo	Mouse

Array 8429-T4

• ILT4/CD85d/LILRB2 Antibodies
• ILT4/CD85d/LILRB2 Lysates
• ILT4/CD85d/LILRB2 Proteins and Enzymes